Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Above 50 Day Moving Average - Here's What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report)'s stock price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $9.71 and traded as high as $10.04. Astellas Pharma shares last traded at $9.99, with a volume of 80,077 shares changing hands.

Astellas Pharma Stock Up 0.3 %

The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 0.39. The firm has a 50 day moving average price of $9.73 and a two-hundred day moving average price of $10.44. The company has a market capitalization of $17.97 billion, a price-to-earnings ratio of -45.13 and a beta of 0.29.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last announced its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share (EPS) for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. As a group, sell-side analysts expect that Astellas Pharma Inc. will post 0.42 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.